Nabriva Therapeutics (Austria) a clinical-stage based developer of antibiotics for treating multi-drug resistant pathogens, closed a $22M Series B financing. Participants include Nomura Phase 4 Ventures, HBM Partners, Wellcome Trust, GLS Ventures and Novartis Venture Fund.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb.